Recently, SIRT2 inhibition has been proposed as a promising therapeutic strategy to achieve neuroprotection in in vitro and in vivo models of Parkinson’s and Huntington’s diseases (Outeiro et al., 2007; Luthi-Carter et al., 2010). The gene discussed is SIRT2; the disease is Parkinson disease.